NCT05213585

Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%

Status unknown Phase 1 Last updated 28 January 2022

What this trial tests

Phase 1 trial testing Ivermectin cream in The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves in 20 participants. Status unknown.

Timeline

24 August 2021

Primary endpoint
30 May 2022

31 December 2022

Quick facts

Lead sponsor	Helm Vision Group
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	24 August 2021
Primary completion	30 May 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

• Ivermectin cream

Conditions studied

• The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves — all drugs for The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves →

Sponsor

Helm Vision Group

Who can join

18 and older, any sex, with The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with Demodex infestation of the eyelids will have the sleeves from both eyes cleaned off with microblepharoexfoliation. Afterwards, one eye will be randomly selected for treatment with topical ivermectin 1% cream. The treatment will be repeated on that eye 2 weeks later. Afterwards, the patients will present monthly for photographs of the eyelashes. The photographs will be reviewed by an ophthalmologist outside of our institution who will be blind to which eye was treated and independently grade the amount of sleeves in each eye. The follow-up will be for 6 months after the second treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.